Have a feature idea you'd love to see implemented?
Let us know!
POAI Predictive Oncology Inc
Price (delayed)
$0.689
Market cap
$4.59M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$3.05
Enterprise value
$3.91M
Predictive Oncology operates through three segments (Skyline, Helomics and Soluble Biotech), which contain four subsidiaries: Helomics, TumorGenesis, Skyline Medical and Soluble Biotech. Helomics applies artificial intelligence to its rich data
Highlights
The EPS has increased by 34% YoY and by 9% from the previous quarter
The company's debt fell by 24% YoY and by 11% QoQ
Predictive Oncology's equity has shrunk by 83% YoY and by 52% QoQ
Predictive Oncology's quick ratio has shrunk by 69% YoY and by 25% QoQ
Key stats
What are the main financial stats of POAI
Market
Valuations
Earnings
Shares outstanding
6.67M
Market cap
$4.59M
Enterprise value
$3.91M
Price to earnings (P/E)
N/A
Price to book (P/B)
2.34
Price to sales (P/S)
3.2
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.84
Revenue
$1.38M
EBIT
-$13.97M
EBITDA
-$13.69M
Free cash flow
-$12.89M
Per share
Balance sheet
Liquidity
EPS
-$3.05
Free cash flow per share
-$2.02
Book value per share
$0.3
Revenue per share
$0.22
TBVPS
$1.14
Total assets
$7.5M
Total liabilities
$5.53M
Debt
$2.4M
Equity
$1.97M
Working capital
$750,642
Debt to equity
1.22
Current ratio
1.2
Quick ratio
0.93
Net debt/EBITDA
0.05
Margins
Efficiency
Dividend
EBITDA margin
-992.7%
Gross margin
43.1%
Net margin
-1,013%
Operating margin
-961.5%
Return on assets
-129.6%
Return on equity
-303.9%
Return on invested capital
-418.7%
Return on capital employed
-379.5%
Return on sales
-1,013%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
POAI stock price
How has the Predictive Oncology stock price performed over time
Intraday
5.58%
1 week
-6.9%
1 month
3.73%
1 year
-77.11%
YTD
-79.06%
QTD
-12.56%
Financial performance
How have Predictive Oncology's revenue and profit performed over time
Revenue
$1.38M
Gross profit
$593,828
Operating income
-$13.26M
Net income
-$13.97M
Gross margin
43.1%
Net margin
-1,013%
POAI's gross profit has dropped by 52% year-on-year and by 42% since the previous quarter
Predictive Oncology's gross margin has decreased by 38% YoY and by 28% QoQ
POAI's operating income is up by 27% YoY and by 3.5% QoQ
POAI's net income is up by 24% year-on-year
Growth
What is Predictive Oncology's growth rate over time
Valuation
What is Predictive Oncology stock price valuation
P/E
N/A
P/B
2.34
P/S
3.2
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.84
The EPS has increased by 34% YoY and by 9% from the previous quarter
Predictive Oncology's equity has shrunk by 83% YoY and by 52% QoQ
The price to book (P/B) is 46% more than the 5-year quarterly average of 1.6 and 17% more than the last 4 quarters average of 2.0
The P/S is 83% lower than the 5-year quarterly average of 19.2 and 33% lower than the last 4 quarters average of 4.8
POAI's revenue is down by 22% YoY and by 19% from the previous quarter
Efficiency
How efficient is Predictive Oncology business performance
The company's return on equity has shrunk by 175% YoY and by 52% QoQ
The return on assets has dropped by 58% year-on-year and by 24% since the previous quarter
The ROS has decreased by 23% from the previous quarter but it has increased by 2.7% YoY
Predictive Oncology's ROIC has decreased by 16% from the previous quarter but it has increased by 14% YoY
Dividends
What is POAI's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for POAI.
Financial health
How did Predictive Oncology financials performed over time
The company's total assets is 36% higher than its total liabilities
Predictive Oncology's quick ratio has shrunk by 69% YoY and by 25% QoQ
The current ratio has dropped by 63% year-on-year and by 19% since the previous quarter
The company's debt is 22% higher than its equity
The debt to equity has soared by 85% from the previous quarter
Predictive Oncology's equity has shrunk by 83% YoY and by 52% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.